Imara Shares Climb 29% After Hours on Merger Plans with Enliven Therapeutics

Dow Jones2022-10-14

By Kathryn Hardison

Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal.

The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday.

The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticker ELVN.

The combined company is expected to have about $300 million of cash and cash equivalents at closing, after transaction expenses. That should advance Enliven's pipeline through multiple clinical milestones and provide runway into early 2026, the companies said.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

October 13, 2022 17:45 ET (21:45 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2275771706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-10-14 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2275771706","market":"hk","top_or_hot":-1,"title":"Imara Shares Climb 29% After Hours on Merger Plans with Enliven Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kathryn Hardison \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/IMRA\">Imara Inc.</a> jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal. \n</p>\n<p>\n  The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday. \n</p>\n<p>\n  The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticker ELVN. \n</p>\n<p>\n  The combined company is expected to have about $300 million of cash and cash equivalents at closing, after transaction expenses. That should advance Enliven's pipeline through multiple clinical milestones and provide runway into early 2026, the companies said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 13, 2022 17:45 ET (21:45 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imara Shares Climb 29% After Hours on Merger Plans with Enliven Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImara Shares Climb 29% After Hours on Merger Plans with Enliven Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-10-14 05:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kathryn Hardison \n\n\n \n\n\n  Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal. \n\n\n  ...</p>\n\n<a href=\"http://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2275771706","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2275771706","pubTimestamp":1665697500,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal.The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday.The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticke","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"Imara股价因与Enliven Therapeutics的合并计划而在盘后上涨29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRA":1},"content_text":"By Kathryn Hardison \n\n\n \n\n\n  Shares of Imara Inc. jumped 29% to $3.33 during after-hours trading on Thursday after it and Enliven Therapeutics Inc. detailed plans to merge in an all-stock deal. \n\n\n  The combined company, if approved by shareholders, would focus on Enliven's pipeline of precision oncology product candidates and would be called Enliven Therapeutics Inc., the companies said Thursday. \n\n\n  The deal is expected to close in the first quarter of next year, with shares trading on the Nasdaq Global Select Market under the ticker ELVN. \n\n\n  The combined company is expected to have about $300 million of cash and cash equivalents at closing, after transaction expenses. That should advance Enliven's pipeline through multiple clinical milestones and provide runway into early 2026, the companies said. \n\n\n \n\n\n  Write to Kathryn Hardison at kathryn.hardison@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2022 17:45 ET (21:45 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2275771706"}